Thomas Cluzeau, MD, PhD
Articles
Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS
Guillermo Garcia-Manero, MD;Rami Komrokji, MD;Esther Natalie Oliva, MD ;Amer Zeidan, MBBS, MHS;Thomas Cluzeau, MD, PhD
June 28th 2024Key opinion leaders address various challenges linked to lower-risk myelodysplastic syndromes, with a focus on cytopenias.
Read More
Guillermo Garcia-Manero, MD;Rami Komrokji, MD;Esther Natalie Oliva, MD ;Amer Zeidan, MBBS, MHS;Thomas Cluzeau, MD, PhD
June 28th 2024The expert panel in hematologyists examines recent WHO and ICC guideline updates, evaluating their impact on the evolving treatment landscape for myelodysplastic syndromes.
Read More
Latest Updated Articles
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Published: July 2nd 2024 | Updated: July 4th 2024
Improving CAR T-Cell Therapy in Multiple Myeloma
Published: June 4th 2024 | Updated: July 4th 2024
Dr McGregor on the Rationale for the DAD Trial in Metastatic Urothelial Cancer
Published: June 28th 2024 | Updated: July 4th 2024
Dr Wirth on the Full FDA Approval of Selpercatinib for Advanced RET Fusion+ Thyroid Cancer
Published: June 4th 2024 | Updated: July 4th 2024
Dr McGregor on the DAD-IO Trial in Treatment-Naive Metastatic Urothelial Carcinoma
Published: July 1st 2024 | Updated: July 4th 2024
TAP Score and CPS May Be Viable for PD-L1 Expression Measurement in Advanced Gastric Cancers
